• Skip to primary navigation
  • Skip to main content
  • Skip to footer
AKRN

AKRN

Scientific Consulting

  • Services
    • Clinical Services
    • Regulatory Services
    • Quality Management Services
    • Medical Writing
    • Clinical Data Management
    • Statistical Analysis and Reporting
    • Medical Aesthetic Devices
    • COVID-19
  • Team
    • Who we are
    • Our team
    • Code of Ethics
    • Our history
    • Our Community
  • News
    • News
    • Resources
    • Social Network
  • Career Portal
  • Contact
  • English
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Progressive roll-out of the IVDR: extended timelines for certain IVDs

February 21, 2022 by AKRN

By the end of 2021, the European Parliament adopted the proposal of the European Commission to amend the EU 2017/746 in vitro diagnostic medical device (IVD). This new position extends the IVDR transition timelines for manufacturers of certain IVDs, providing a progressive roll-out and aiming to avoid the disruption in the supply of IVDs to the European market.

Collection of IVD medical devices: Digital glucometer and lancet pen, stethoscope, blood in vitro, on white background, concept of health, medical technology, patient monitoring.

Background and IVD regulatory landscape in Europe

The European IVD Regulation (IVDR 2017/746) will become fully applicable from May 26, 2022, thus repealing the previous directive (98/79/EC). Such replacement strengthens the regulatory framework by which IVDs are placed in the market, including their risk classification. Under this new regulation, approximately 80% of IVDs are expected to require the assessment of notified bodies; it is important to note that this percentage ranged between 10 and 20% under the directive. However, the number of notified bodies designated under the IVDR remains pretty limited (6 so far). Moreover, the difficulties arising from the COVID-19 pandemic have contributed to the delay in the designation of such bodies and the prediction of a lack of IVDs on the market. Given that 70% of clinical decisions are made using these devices, inaction by the European authorities was unacceptable.

Softer transition timelines for IVDs

Consequently, the European Commission has drafted an amendment to the regulation to extend the number of devices eligible for a “soft” transition. This way, IVDs placed on the market under Directive 98/79/EC and requiring the involvement of a notified body under the new regulation will be able to continue on the market until the following dates:

  • May 26, 2025, for Class D devices.
  • May 26, 2026, for class C devices.
  • May 26, 2027, for Class B and Class A sterile devices.

Nevertheless, be aware that IVDR’s requirements for post-market surveillance, market surveillance, vigilance and registration of devices, and economic operators must be applied from May 26, 2022. You can see a brief checklist of how to bring IVDs into compliance with the IVDR here.

How can AKRN help IVD manufacturers?

  • Quality Experts: development and implementation of processes in accordance with EN ISO 13485 to comply with IVDR requirements on post-market surveillance, vigilance, market surveillance, and communication with economic operators, among many others.
  • Regulatory Experts: strategic guidance, evaluation and preparation of regulatory documentation, including technical documentation and performance evaluation documentation.
  • Clinical Experts: support manufacturers in designing, executing and monitoring clinical performance studies according to EN ISO 20916.
Contact us

Subject Matter Experts

Arancha López-Pérez, Ph.D.
Regulatory Affairs Scientist LinkedIn

Albert Negrete, Ph.D.
Regulatory Affairs Scientist LinkedIn

Share this article

Category iconCE Mark,  European Union,  In vitro diagnostic devices,  IVDR,  Medical Technology,  MedTech,  Notified Body,  Regulatory Affairs Tag iconArticle 110,  EU IVD regulation 2016/746 (IVDR),  Extension period,  In vitro diagnostics medical devices (IVDs),  IVDD transition,  IVDR,  Legacy devices,  notified bodies under IVDR,  Notified body

Request a free consultation

Our team will help you to find the best solution for your needs. Our medical device experience and clinical knowledge can help you plan, set up, and execute a clinical trial, or performance study, in an optimal way.

Footer

AKRN Spain

AKRN Scientific Consulting S.L.
Address: Calle de Fuerteventura 4 (office 1.8)
Office Park La Marina
Postal Code: ES-28703 Madrid
Phone: +34 910 25 81 40
VAT ID: ES-B87990925

Contact details

Contact email: contact@akrnconsulting.com
Office phone: +34 910 258 140
Office phone: +34 919 333 814
Go to contact

Content

  • Medical Device Consulting Services
  • Clinical Studies for Medical Devices
  • Medical Writing
  • Regulatory Services
  • Contact

Resources

  • Articles
  • Resources
  • Career Portal

Latest articles

  • Artificial Intelligence challenges in Medical Devices
  • What is good clinical practice (GCP)?
  • Drug or Device? Summary and analysis of MDCG 2022-05 on borderline products
  • TRANSITIONAL PROVISIONS according to (EU) 2017/746 ARTICLE 110 IVDR, AN UPDATE WITH MDCGs published in 2022.
  • FELLOW PROGRAM – THE TALENT INCUBATOR OF A CRO
  • AUDITING A QMS ACCORDING TO ISO 13485

AKRN, Now part of NAMSA, is now ISO 9001:2015 quality certified by EQA, a recognized Spanish accredited certification body. The ISO 9001 standard, established by the International Organization for Standardization (ISO), is the quality standard par excellence, and its structure forms the basis for other quality standards such as the medical device quality standard ISO 13485. Implementing ISO 9001:2015 aims to support organizations in enhancing their overall performance and client satisfaction.

AKRN Scientific Consulting S.L ha sido beneficiaria del Fondo Europeo de Desarrollo Regional cuyo objetivo es mejorar la competitividad de las Pymes y gracias al cual ha puesto en marcha un Plan de Marketing Digital Internacional con el objetivo de mejorar su posicionamiento online en mercados exteriores durante el año 2020. Para ello ha contado con el apoyo del Programa XPANDE DIGITAL de la Cámara de Comercio de Burgos.
“Una manera de hacer Europa”

AKRN Scientific Consulting S.L ha sido beneficiaria de la subvención de contratos de trabajo de la Comunidad de Madrid, cofinanciado por el Fondo Social Europeo y la Iniciativa de Empleo Juvenil, en el marco del Programa Operativo de Empleo Juvenil 2014-2020, gestionado por la Consejería de Economía, Empleo y Hacienda.

La empresa (AKRN Scientific Consulting S.L.) es beneficiaria del Programa “la Caixa” Empleo Joven de ayudas para el fomento de la contratación de personas jóvenes. Estas ayudas están cofinanciadas por el Programa Operativo de Empleo Juvenil / Iniciativa de Empleo Juvenil – Fondo Social Europeo y por la Fundación Bancaria “la Caixa”.

 

 

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Privacy policy – Cookie Policy – Legal Notice –  Copyright © 2023. All rights reserved. Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
AKRN

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy